BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28219443)

  • 1. A new framework for evaluating the health impacts of treatment for Gaucher disease type 1.
    Ganz ML; Stern S; Ward A; Nalysnyk L; Selzer M; Hamed A; Weinreb N
    Orphanet J Rare Dis; 2017 Feb; 12(1):38. PubMed ID: 28219443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).
    Weinreb NJ; Finegold DN; Feingold E; Zeng Z; Rosenbloom BE; Shankar SP; Amato D
    Orphanet J Rare Dis; 2015 May; 10():64. PubMed ID: 25994334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlating liver stiffness with disease severity scoring system (DS3) values in Gaucher disease type 1 (GD1) patients.
    Serai SD; Naidu AP; Andrew Burrow T; Prada CE; Xanthakos S; Towbin AJ
    Mol Genet Metab; 2018 Mar; 123(3):357-363. PubMed ID: 29361370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaucher disease: hematologic and oncologic implications.
    Hughes D
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):771-2. PubMed ID: 22252578
    [No Abstract]   [Full Text] [Related]  

  • 5. Retrospective Analysis of Whole-Body Magnetic Resonance Imaging of Bone Manifestations in Long-Term Treated Patients with Gaucher Disease Type 1.
    Lollert A; Laudemann K; Mengel E; Hoffmann C; Moos L; Reinke J; Brixius-Huth M; Hennermann JB; Düber C; Staatz G
    Klin Padiatr; 2019 Mar; 231(2):52-59. PubMed ID: 30481833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
    Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
    Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
    Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
    [No Abstract]   [Full Text] [Related]  

  • 8. A validated disease severity scoring system for adults with type 1 Gaucher disease.
    Weinreb NJ; Cappellini MD; Cox TM; Giannini EH; Grabowski GA; Hwu WL; Mankin H; Martins AM; Sawyer C; vom Dahl S; Yeh MS; Zimran A
    Genet Med; 2010 Jan; 12(1):44-51. PubMed ID: 20027115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Goal-oriented therapy with miglustat in Gaucher disease.
    Pastores GM; Giraldo P; Chérin P; Mehta A
    Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C; Swiader L; Serratrice J
    J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM; Elstein D; Hrebícek M; Zimran A
    Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
    Moyses C
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy.
    Stein P; Malhotra A; Haims A; Pastores GM; Mistry PK
    J Inherit Metab Dis; 2010 Dec; 33(6):769-74. PubMed ID: 20683668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
    Deegan P; Khan A; Camelo JS; Batista JL; Weinreb N
    Orphanet J Rare Dis; 2021 Feb; 16(1):92. PubMed ID: 33602299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
    Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B
    Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
    Camou F; Viallard JF
    Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
    [No Abstract]   [Full Text] [Related]  

  • 18. Gaucher disease and its treatment options.
    Bennett LL; Mohan D
    Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic goals in Gaucher disease.
    Mistry P; Germain DP
    Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
    Giraldo P; Andrade-Campos M; Alfonso P; Irun P; Atutxa K; Acedo A; Barez A; Blanes M; Diaz-Morant V; Fernández-Galán MA; Franco R; Gil-Cortes C; Giner V; Ibañez A; Latre P; Loyola I; Luño E; Hernández-Martin R; Medrano-Engay B; Puerta J; Roig I; de la Serna J; Salamero O; Villalón L; Pocovi M
    Blood Cells Mol Dis; 2018 Feb; 68():173-179. PubMed ID: 27836529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.